Literature DB >> 33424457

Insights into the Neurobiology of Craving in Opioid Use Disorder.

Lindsay M Lueptow1,2,3, Elizabeth C Shashkova2,4, Margaret G Miller2,4, Christopher J Evans1,2,5,4, Catherine M Cahill1,2,5,4.   

Abstract

PURPOSE OF REVIEW: Opioids remain the most potent form of pain relief currently available, yet have a high abuse liability. Here we discuss underlying neurobiological changes in Opioid Use Disorder (OUD) that likely contribute to drug craving, which in turn drives continued drug use and relapse. RECENT
FINDINGS: Craving has emerged as a strong indicator in drug-seeking and relapse. Studies have demonstrated a number of allostatic changes in circuitry that facilitate learning of drug-stimuli relationships, thereby augmenting cue-triggered drug use and relapse.
SUMMARY: This review will focus on key neurobiological changes in underlying circuitry observed during the initial and continued exposure to opioids that result in an increase in neural-reactivity to drug-related intrinsic and extrinsic drug cues, and to enhanced learning of drug-context correlations. This sensitized learning state may be an indication of the underlying framework that drives craving and ultimately, motivates increased salience of drug cues and drives drug-seeking.

Entities:  

Keywords:  Drug craving; Incentive sensitization; Negative affect; Negative reinforcement; Opioid Use Disorder; Stress

Year:  2020        PMID: 33424457      PMCID: PMC7790122          DOI: 10.1007/s40140-020-00420-7

Source DB:  PubMed          Journal:  Curr Anesthesiol Rep        ISSN: 1523-3855


  93 in total

1.  Gender differences in the intravenous self-administration of mu opiate agonists.

Authors:  Theodore J Cicero; Shawn C Aylward; Edward R Meyer
Journal:  Pharmacol Biochem Behav       Date:  2003-02       Impact factor: 3.533

2.  Conditioned withdrawal drives heroin consumption and decreases reward sensitivity.

Authors:  Paul J Kenny; Scott A Chen; Osamu Kitamura; Athina Markou; George F Koob
Journal:  J Neurosci       Date:  2006-05-31       Impact factor: 6.167

3.  Extended heroin access increases heroin choices over a potent nondrug alternative.

Authors:  Magalie Lenoir; Lauriane Cantin; Nathalie Vanhille; Fuschia Serre; Serge H Ahmed
Journal:  Neuropsychopharmacology       Date:  2013-01-15       Impact factor: 7.853

Review 4.  Reward and motivation in pain and pain relief.

Authors:  Edita Navratilova; Frank Porreca
Journal:  Nat Neurosci       Date:  2014-09-25       Impact factor: 24.884

5.  A case report illustrating the effects of repetitive transcranial magnetic stimulation on cue-induced craving in an individual with opioid and cocaine use disorder.

Authors:  James J Mahoney; Patrick J Marshalek; Ali R Rezai; Laura R Lander; James H Berry; Marc W Haut
Journal:  Exp Clin Psychopharmacol       Date:  2020-02       Impact factor: 3.157

6.  Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats.

Authors:  W J Lynch; M E Carroll
Journal:  Psychopharmacology (Berl)       Date:  1999-05       Impact factor: 4.530

Review 7.  Pleasure systems in the brain.

Authors:  Kent C Berridge; Morten L Kringelbach
Journal:  Neuron       Date:  2015-05-06       Impact factor: 17.173

Review 8.  Common Brain Mechanisms of Chronic Pain and Addiction.

Authors:  Igor Elman; David Borsook
Journal:  Neuron       Date:  2016-01-06       Impact factor: 17.173

9.  Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.

Authors:  Scott M Hyman; Helen Fox; Kwang-Ik A Hong; Cheryl Doebrick; Rajita Sinha
Journal:  Exp Clin Psychopharmacol       Date:  2007-04       Impact factor: 3.157

10.  A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.

Authors:  Andrew D Krystal; Diego A Pizzagalli; Moria Smoski; Sanjay J Mathew; John Nurnberger; Sarah H Lisanby; Dan Iosifescu; James W Murrough; Hongqiu Yang; Richard D Weiner; Joseph R Calabrese; Gerard Sanacora; Gretchen Hermes; Richard S E Keefe; Allen Song; Wayne Goodman; Steven T Szabo; Alexis E Whitton; Keming Gao; William Z Potter
Journal:  Nat Med       Date:  2020-03-30       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.